Assembly Biosciences (NASDAQ:ASMB) Insider Sells $14,263.74 in Stock

Posted by Stanley Muller on Nov 6th, 2026

Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) insider Jeanette Bjorkquist sold 727 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $19.62, for a total transaction of $14,263.74. Following the completion of the transaction, the insider directly owned 17,673 shares in the company, valued at approximately $346,744.26. The trade was a 3.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Assembly Biosciences Stock Performance

ASMB opened at $20.00 on Friday. The company has a fifty day moving average price of $24.92 and a two-hundred day moving average price of $27.02. Assembly Biosciences, Inc. has a 52 week low of $19.20 and a 52 week high of $39.71. The firm has a market capitalization of $407.20 million, a PE ratio of 19.48 and a beta of 1.26.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. The business had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Equities analysts forecast that Assembly Biosciences, Inc. will post 2.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ASMB. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Thursday, October 15th. Mizuho set a $53.00 price objective on shares of Assembly Biosciences in a report on Tuesday, September 1st. UBS Group lowered their target price on shares of Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $46.50.

Check Out Our Latest Stock Report on ASMB

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors have recently modified their holdings of the business. Engineers Gate Manager LP lifted its stake in Assembly Biosciences by 88.5% in the second quarter. Engineers Gate Manager LP now owns 17,766 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 8,343 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Assembly Biosciences by 43.7% during the second quarter. Squarepoint Ops LLC now owns 34,214 shares of the biopharmaceutical company’s stock worth $940,000 after acquiring an additional 10,410 shares in the last quarter. Seven Fleet Capital Management LP increased its position in shares of Assembly Biosciences by 671.5% during the second quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after acquiring an additional 377,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Assembly Biosciences during the second quarter worth $660,000. Finally, Bank of America Corp DE raised its holdings in shares of Assembly Biosciences by 113.3% during the first quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock worth $303,000 after acquiring an additional 5,792 shares during the period. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral infections. The company’s research programs target chronic hepatitis B virus (HBV) infection and herpesvirus infections, including herpes simplex virus (HSV), with the goal of addressing diseases for which existing treatments may not provide adequate cures or long-term control.

Assembly’s pipeline includes novel antiviral candidates designed to interfere with essential stages of viral replication.